Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

NCT ID: NCT00247429

Last Updated: 2009-09-01

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 59 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2004-07-31
• Study Completion Date: 2005-10-31

Brief Summary

In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.

Conditions

Depressive Syndrome; Anxiety

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients older than 60 years
• Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14

Exclusion Criteria

• Participation in other studies in the last 3 months before the start of the study
• Known hypersensibility to venlafaxine
• Clinically significant abnormalities according to the venlafaxine labeling

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role: lead

Principal Investigators

Medical Monitor

Role: PRINCIPAL_INVESTIGATOR

Wyeth is now a wholly owned subsidiary of Pfizer

Other Identifiers

101356

Identifier Type: -

Identifier Source: org_study_id